↓ Skip to main content

Persistent stromal fibroblast activation is present in chronic tendinopathy

Overview of attention for article published in Arthritis Research & Therapy, January 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)
  • High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

twitter
27 X users
facebook
1 Facebook page

Citations

dimensions_citation
75 Dimensions

Readers on

mendeley
111 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Persistent stromal fibroblast activation is present in chronic tendinopathy
Published in
Arthritis Research & Therapy, January 2017
DOI 10.1186/s13075-016-1218-4
Pubmed ID
Authors

Stephanie G. Dakin, Christopher D. Buckley, Mohammad Hussein Al-Mossawi, Robert Hedley, Fernando O. Martinez, Kim Wheway, Bridget Watkins, Andrew J. Carr

Abstract

Growing evidence supports a key role for inflammation in the onset and progression of tendinopathy. However, the effect of the inflammatory infiltrate on tendon cells is poorly understood. We investigated stromal fibroblast activation signatures in tissues and cells from patients with tendinopathy. Diseased tendons were collected from well-phenotyped patient cohorts with supraspinatus tendinopathy before and after sub-acromial decompression treatment. Healthy tendons were collected from patients undergoing shoulder stabilisation or anterior cruciate ligament repair. Stromal fibroblast activation markers including podoplanin (PDPN), CD106 (VCAM-1) and CD248 were investigated by immunostaining, flow cytometry and RT-qPCR. PDPN, CD248 and CD106 were increased in diseased compared to healthy tendon tissues. This stromal fibroblast activation signature persisted in tendon biopsies in patients at 2-4 years post treatment. PDPN, CD248 and CD106 were increased in diseased compared to healthy tendon cells. IL-1β treatment induced PDPN and CD106 but not CD248. IL-1β treatment induced NF-κB target genes in healthy cells, which gradually declined following replacement with cytokine-free medium, whilst PDPN and CD106 remained above pre-stimulated levels. IL-1β-treated diseased cells had more profound induction of PDPN and CD106 and sustained expression of IL6 and IL8 mRNA compared to IL-1β-treated healthy cells. We conclude that stromal fibroblast activation markers are increased and persist in diseased compared to healthy tendon tissues and cells. Diseased tendon cells have distinct stromal fibroblast populations. IL-1β treatment induced persistent stromal fibroblast activation which was more profound in diseased cells. Persistent stromal fibroblast activation may be implicated in the development of chronic inflammation and recurrent tendinopathy. Targeting this stromal fibroblast activation signature is a potential therapeutic strategy.

X Demographics

X Demographics

The data shown below were collected from the profiles of 27 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 111 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 111 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 21 19%
Student > Ph. D. Student 20 18%
Researcher 12 11%
Student > Bachelor 10 9%
Student > Doctoral Student 5 5%
Other 17 15%
Unknown 26 23%
Readers by discipline Count As %
Medicine and Dentistry 23 21%
Biochemistry, Genetics and Molecular Biology 10 9%
Engineering 9 8%
Sports and Recreations 9 8%
Nursing and Health Professions 7 6%
Other 18 16%
Unknown 35 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 July 2019.
All research outputs
#2,159,304
of 25,476,463 outputs
Outputs from Arthritis Research & Therapy
#379
of 3,391 outputs
Outputs of similar age
#43,497
of 423,033 outputs
Outputs of similar age from Arthritis Research & Therapy
#9
of 49 outputs
Altmetric has tracked 25,476,463 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,391 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.2. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 423,033 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 49 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.